Zubirán Rafael, Neufeld Edward B, Dasseux Amaury, Remaley Alan T, Sorokin Alexander V
Lipoprotein Metabolism Laboratory, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Section of Inflammation and Cardiometabolic Diseases, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Cardiol Ther. 2024 Sep;13(3):465-491. doi: 10.1007/s40119-024-00376-3. Epub 2024 Jul 20.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality despite effective low-density lipoprotein cholesterol-targeted therapies. This review explores the crucial role of inflammation in the residual risk of ASCVD, emphasizing its impact on atherosclerosis progression and plaque stability. Evidence suggests that high-sensitivity C-reactive protein (hsCRP), and potentially other inflammatory biomarkers, can be used to identify the inflammatory residual ASCVD risk phenotype and may serve as future targets for the development of more efficacious therapeutic approaches. We review the biological basis for the association of inflammation with ASCVD, propose new therapeutic strategies for the use of inflammation-targeted treatments, and discuss current challenges in the implementation of this new treatment paradigm for ASCVD.
尽管有针对低密度脂蛋白胆固醇的有效治疗方法，但动脉粥样硬化性心血管疾病（ASCVD）仍然是发病和死亡的主要原因。本综述探讨了炎症在ASCVD残余风险中的关键作用，强调其对动脉粥样硬化进展和斑块稳定性的影响。有证据表明，高敏C反应蛋白（hsCRP）以及其他潜在的炎症生物标志物可用于识别炎症性ASCVD残余风险表型，并可能成为开发更有效治疗方法的未来靶点。我们回顾了炎症与ASCVD关联的生物学基础，提出了使用炎症靶向治疗的新策略，并讨论了在实施这种针对ASCVD的新治疗模式时当前面临的挑战。
Zotero 插件
